Latest News Archive
Please select Category, Year, and then Month to display items
23 November 2022
|
Story André Damons
![]()
Prof Motlalepula Matsabisa, Professor and Director of Pharmacology, will play host to the various stakeholders to network and share knowledge on current developments in indigenous knowledge research and product development, biodiversity, innovation, and commercialisation of the IK-based research products. The Indigenous Knowledge System (IKS) for Health unit in the Department of Pharmacology within the UFS Faculty of Health Sciences was last year awarded an annual Technology Innovation Agency Platform (TIA) grant of R17 million for the next five years.
The research and teaching programme in the School of Clinical Medicine has since been rebranded and is now known as the African Medicines Innovation and Technology Development Platform (AMITD), which will strive to respond to community health needs and address industry research needs and challenges.
The indaba will showcase progress made by TIA and other entities in enriching the development and commercialisation of IK-based innovations. It will take place from 24 to 25 November 2022 in the Equitas Senate Hall at the UFS.
Prof Matsabisa is the chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19. He is also a visiting professor at the Beijing University of Chinese Medicine (BUCM) in Beijing, China, and the Deputy President of the South African Society for Basic and Clinical Pharmacology.
SADoCoL receives partial reinstatement of blood sample testing by the World Anti-Doping Agency
2016-08-22
Last week, the World Anti-Doping Agency (WADA) announced the lifting of the suspension of blood sample analysis by the South African Doping Control Laboratory (SADoCoL) at the University of the Free State (UFS). Although the suspension of urine sample analysis is still under review, the UFS is appreciative of the new outcome. The initial temporary suspension of SADoCoL, announced on 3 May 2016, included the suspension of all doping-control procedures which applied to both urine and blood samples.
The main reason for the suspension involved analytical techniques relevant to urine analysis; however, the testing of blood samples was also included in the suspension. At the time of the suspension, no adverse findings were reported for the laboratory in relation to blood-sample testing for Athlete Blood Passport (ABP) assessment.
According to the agreement with WADA, the suspension period would be utilised to implement and test new systems in order to achieve the standard presently required by WADA, as well as to perform development and improvements. SADoCoL is a specialised service laboratory of the UFS and has been in existence for more than thirty years.
Upon SADoCoL’s request to lift the suspension of only the ABP analysis, WADA agreed to allow the laboratory to apply for reaccreditation. SADoCoL immediately applied for reaccreditation of ABP analysis on blood, so that the laboratory would be allowed to at least offer this service to the Anti-Doping community in Africa.
For this purpose, inspections were performed by the South African National Accreditation System (SANAS) and by WADA, during which all aspects of blood analysis by the laboratory were thoroughly assessed and tested. The successful outcome of these inspections resulted in the reaccreditation of SADoCoL by WADA in order to perform ABP analysis as required by the WADA International Standard for Laboratories, with effect from 4 August 2016.
This outcome allows the laboratory to once again perform this very essential analytical procedure. The South African Institute for Drug-Free Sport (SAIDS) and other regular users can now continue to send blood samples to SADoCoL for ABP analysis, instead of making use of alternative laboratories.
Released by: Lacea Loader (Director: Communication and Brand Management)
Tel: +27 51 401 3422/2707 or +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27 51 444 6393